2 401

Cited 0 times in

High-dose-rate intracavitary radiotherapy in the management of cervical intraepithelial neoplasia 3 and carcinoma in situ presenting with poor histologic factors after undergoing excisional procedures.

DC FieldValueLanguage
dc.contributor.author김상운-
dc.contributor.author김성훈-
dc.contributor.author김영태-
dc.contributor.author김용배-
dc.contributor.author남은지-
dc.contributor.author조남훈-
dc.contributor.author금웅섭-
dc.contributor.author김귀언-
dc.date.accessioned2014-12-19T16:58:23Z-
dc.date.available2014-12-19T16:58:23Z-
dc.date.issued2012-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/90540-
dc.description.abstractPURPOSE: To assess the effectiveness of high-dose-rate intracavitary radiotherapy (HDR-ICR) in patients with cervical intraepithelial neoplasia 3 (CIN 3) and carcinoma in situ (CIS) presenting with poor histologic factors for predicting residual disease after undergoing diagnostic excisional procedures. METHODS AND MATERIALS: This study was a retrospective analysis of 166 patients with CIN 3 (n=15) and CIS (n=151) between October 1986 and December 2005. They were diagnosed by conization (n=158) and punch biopsy (n=8). Pathologic analysis showed 135 cases of endocervical gland involvement (81.4%), 74 cases of positive resection margins (44.5%), and 52 cases of malignant cells on endocervical curettage (31.3%). All patients were treated with HDR-ICR using Co⁶⁰ or Ir¹⁹² at a cancer center. The dose was prescribed at point A located 2 cm superior to the external os and 2 cm lateral to the axis of the tandem for intact uterus. RESULTS: Median age was 61 years (range, 29-77). The median total dose of HDR-ICR was 30 Gy/6 fractions (range, 30-52). At follow-up (median, 152 months), 2 patients developed recurrent diseases: 1 CIN 2 and 1 invasive carcinoma. One hundred and forty patients survived and 26 patients died, owing to nonmalignant intercurrent disease. Rectal bleeding occurred in one patient; however, this symptom subsided with conservative management. CONCLUSIONS: Our data showed HDR-ICR is an effective modality for CIN 3 and CIS patients presenting with poor histologic factors after excisional procedures. HDR-ICR should be considered as a definitive treatment in CIN 3 and CIS patients with possible residual disease after undergoing excisional procedures.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHBrachytherapy/methods*-
dc.subject.MESHCarcinoma in Situ/mortality-
dc.subject.MESHCarcinoma in Situ/pathology-
dc.subject.MESHCarcinoma in Situ/radiotherapy*-
dc.subject.MESHCarcinoma in Situ/surgery-
dc.subject.MESHCervical Intraepithelial Neoplasia/mortality-
dc.subject.MESHCervical Intraepithelial Neoplasia/pathology-
dc.subject.MESHCervical Intraepithelial Neoplasia/radiotherapy*-
dc.subject.MESHCervical Intraepithelial Neoplasia/surgery-
dc.subject.MESHCervix Uteri/pathology-
dc.subject.MESHCobalt Radioisotopes/therapeutic use-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIridium Radioisotopes/therapeutic use-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm, Residual-
dc.subject.MESHPostoperative Care-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHUterine Cervical Neoplasms/mortality-
dc.subject.MESHUterine Cervical Neoplasms/pathology-
dc.subject.MESHUterine Cervical Neoplasms/radiotherapy*-
dc.subject.MESHUterine Cervical Neoplasms/surgery-
dc.titleHigh-dose-rate intracavitary radiotherapy in the management of cervical intraepithelial neoplasia 3 and carcinoma in situ presenting with poor histologic factors after undergoing excisional procedures.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학)-
dc.contributor.googleauthorYong Bae Kim-
dc.contributor.googleauthorYoung Tae Kim-
dc.contributor.googleauthorNam Hoon Cho-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorSunghoon Kim-
dc.contributor.googleauthorSang Wun Kim-
dc.contributor.googleauthorEun Ji Nam-
dc.contributor.googleauthorGwi Eon Kim-
dc.identifier.doi22901420-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00744-
dc.contributor.localIdA00595-
dc.contributor.localIdA00526-
dc.contributor.localIdA00729-
dc.contributor.localIdA01262-
dc.contributor.localIdA03812-
dc.contributor.localIdA00273-
dc.contributor.localIdA00321-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid22901420-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0360301612003112-
dc.subject.keywordAdult-
dc.subject.keywordAged-
dc.subject.keywordAged, 80 and over-
dc.subject.keywordBrachytherapy/methods*-
dc.subject.keywordCarcinoma in Situ/mortality-
dc.subject.keywordCarcinoma in Situ/pathology-
dc.subject.keywordCarcinoma in Situ/radiotherapy*-
dc.subject.keywordCarcinoma in Situ/surgery-
dc.subject.keywordCervical Intraepithelial Neoplasia/mortality-
dc.subject.keywordCervical Intraepithelial Neoplasia/pathology-
dc.subject.keywordCervical Intraepithelial Neoplasia/radiotherapy*-
dc.subject.keywordCervical Intraepithelial Neoplasia/surgery-
dc.subject.keywordCervix Uteri/pathology-
dc.subject.keywordCobalt Radioisotopes/therapeutic use-
dc.subject.keywordDisease-Free Survival-
dc.subject.keywordFemale-
dc.subject.keywordHumans-
dc.subject.keywordIridium Radioisotopes/therapeutic use-
dc.subject.keywordMiddle Aged-
dc.subject.keywordNeoplasm, Residual-
dc.subject.keywordPostoperative Care-
dc.subject.keywordRadiotherapy Dosage-
dc.subject.keywordRetrospective Studies-
dc.subject.keywordUterine Cervical Neoplasms/mortality-
dc.subject.keywordUterine Cervical Neoplasms/pathology-
dc.subject.keywordUterine Cervical Neoplasms/radiotherapy*-
dc.subject.keywordUterine Cervical Neoplasms/surgery-
dc.contributor.alternativeNameKim, Sang Wun-
dc.contributor.alternativeNameKim, Sung Hoon-
dc.contributor.alternativeNameKim, Young Tae-
dc.contributor.alternativeNameKim, Yong Bae-
dc.contributor.alternativeNameNam, Eun Ji-
dc.contributor.alternativeNameCho, Nam Hoon-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.alternativeNameKim, Gwi Eon-
dc.contributor.affiliatedAuthorKim, Yong Bae-
dc.contributor.affiliatedAuthorKim, Sung Hoon-
dc.contributor.affiliatedAuthorKim, Sang Wun-
dc.contributor.affiliatedAuthorKim, Young Tae-
dc.contributor.affiliatedAuthorNam, Eun Ji-
dc.contributor.affiliatedAuthorCho, Nam Hoon-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.contributor.affiliatedAuthorKim, Gwi Eon-
dc.citation.volume84-
dc.citation.number1-
dc.citation.startPage19-
dc.citation.endPage22-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.84(1) : 19-22, 2012-
dc.identifier.rimsid32822-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.